Literature DB >> 26454360

Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd edition.

Vikram Patel1, Dan Chisholm2, Rachana Parikh3, Fiona J Charlson4, Louisa Degenhardt5, Tarun Dua2, Alize J Ferrari4, Steve Hyman6, Ramanan Laxminarayan7, Carol Levin8, Crick Lund9, María Elena Medina Mora10, Inge Petersen11, James Scott12, Rahul Shidhaye13, Lakshmi Vijayakumar14, Graham Thornicroft15, Harvey Whiteford16.   

Abstract

The burden of mental, neurological, and substance use (MNS) disorders increased by 41% between 1990 and 2010 and now accounts for one in every 10 lost years of health globally. This sobering statistic does not take into account the substantial excess mortality associated with these disorders or the social and economic consequences of MNS disorders on affected persons, their caregivers, and society. A wide variety of effective interventions, including drugs, psychological treatments, and social interventions, can prevent and treat MNS disorders. At the population-level platform of service delivery, best practices include legislative measures to restrict access to means of self-harm or suicide and to reduce the availability of and demand for alcohol. At the community-level platform, best practices include life-skills training in schools to build social and emotional competencies. At the health-care-level platform, we identify three delivery channels. Two of these delivery channels are especially relevant from a public health perspective: self-management (eg, web-based psychological therapy for depression and anxiety disorders) and primary care and community outreach (eg, non-specialist health worker delivering psychological and pharmacological management of selected disorders). The third delivery channel, hospital care, which includes specialist services for MNS disorders and first-level hospitals providing other types of services (such as general medicine, HIV, or paediatric care), play an important part for a smaller proportion of cases with severe, refractory, or emergency presentations and for the integration of mental health care in other health-care channels, respectively. The costs of providing a significantly scaled up package of specified cost-effective interventions for prioritised MNS disorders in low-income and lower-middle-income countries is estimated at US$3-4 per head of population per year. Since a substantial proportion of MNS disorders run a chronic and disabling course and adversely affect household welfare, intervention costs should largely be met by government through increased resource allocation and financial protection measures (rather than leaving households to pay out-of-pocket). Moreover, a policy of moving towards universal public finance can also be expected to lead to a far more equitable allocation of public health resources across income groups. Despite this evidence, less than 1% of development assistance for health and government spending on health in low-income and middle-income countries is allocated to the care of people with these disorders. Achieving the health gains associated with prioritised interventions will require not just financial resources, but committed and sustained efforts to address a range of other barriers (such as paucity of human resources, weak governance, and stigma). Ultimately, the goal is to massively increase opportunities for people with MNS disorders to access services without the prospect of discrimination or impoverishment and with the hope of attaining optimal health and social outcomes.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26454360     DOI: 10.1016/S0140-6736(15)00390-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  196 in total

1.  Childhood antecedents of schizophrenia: Will understanding aetiopathogenesis result in schizophrenia prevention?

Authors:  James G Scott
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-01-29       Impact factor: 4.328

2.  Comparative Transcriptomic Analysis of the Effects of Antidepressant Drugs in Stress-Susceptible Mice.

Authors:  Florian Duclot; Mohamed Kabbaj
Journal:  Biol Psychiatry       Date:  2017-02-15       Impact factor: 13.382

3.  Evaluation of Proactive Community Case Detection to Increase Help Seeking for Mental Health Care: A Pragmatic Randomized Controlled Trial.

Authors:  Mark J D Jordans; Nagendra P Luitel; Crick Lund; Brandon A Kohrt
Journal:  Psychiatr Serv       Date:  2020-04-23       Impact factor: 3.084

4.  Sex Differences in the Pharmacokinetics of Low-dose Ketamine in Plasma and Brain of Male and Female Rats.

Authors:  Samantha K Saland; Mohamed Kabbaj
Journal:  J Pharmacol Exp Ther       Date:  2018-09-13       Impact factor: 4.030

5.  A little could go a long way: financing for mental healthcare in low- and middle-income countries.

Authors:  L Asher; M J De Silva
Journal:  Epidemiol Psychiatr Sci       Date:  2017-01-09       Impact factor: 6.892

6.  Effectiveness of psychological treatments for depression and alcohol use disorder delivered by community-based counsellors: two pragmatic randomised controlled trials within primary healthcare in Nepal.

Authors:  Mark J D Jordans; Nagendra P Luitel; Emily Garman; Brandon A Kohrt; Sujit D Rathod; Pragya Shrestha; Ivan H Komproe; Crick Lund; Vikram Patel
Journal:  Br J Psychiatry       Date:  2019-01-25       Impact factor: 9.319

Review 7.  Development and evaluation of addiction treatment programs in Latin America.

Authors:  Rodrigo Marín-Navarrete; María Elena Medina-Mora; Alejandro Pérez-López; Viviana E Horigian
Journal:  Curr Opin Psychiatry       Date:  2018-07       Impact factor: 4.741

8.  Implications of Drug Use Disorders on Spine Surgery.

Authors:  Christopher S Ferari; Gennadiy A Katsevman; Patricia Dekeseredy; Cara L Sedney
Journal:  World Neurosurg       Date:  2020-01-08       Impact factor: 2.104

9.  Opportunities and challenges in modeling human brain disorders in transgenic primates.

Authors:  Charles G Jennings; Rogier Landman; Yang Zhou; Jitendra Sharma; Julia Hyman; J Anthony Movshon; Zilong Qiu; Angela C Roberts; Anna Wang Roe; Xiaoqin Wang; Huihui Zhou; Liping Wang; Feng Zhang; Robert Desimone; Guoping Feng
Journal:  Nat Neurosci       Date:  2016-08-26       Impact factor: 24.884

10.  Improving education, policy and research in mental health worldwide: the role of the WPA Collaborating Centres.

Authors:  Kamaldeep S Bhui; Andrea Fiorillo; Dan Stein; Tarek Okasha; David Ndetei; Linda Lam; Santosh Chaturvedi; Mario Maj
Journal:  World Psychiatry       Date:  2016-10       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.